Fixed-dose Combination (Polypill) for Myocardial Infarction Prevention: A Meta-analysis of Randomized Controlled Trials.

IF 1.9 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiology Pub Date : 2025-06-10 DOI:10.1159/000546788
Shenshen Zhang, Xi Chen, Bing Liu, Guangjie Shu, Junyan Li, Huiru Huang, Wenxin Lu, Xiaoshuang Hu, Jia Wang, Ruizhe Hu
{"title":"Fixed-dose Combination (Polypill) for Myocardial Infarction Prevention: A Meta-analysis of Randomized Controlled Trials.","authors":"Shenshen Zhang, Xi Chen, Bing Liu, Guangjie Shu, Junyan Li, Huiru Huang, Wenxin Lu, Xiaoshuang Hu, Jia Wang, Ruizhe Hu","doi":"10.1159/000546788","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Myocardial infarction (MI) is one of the leading causes of death from cardiovascular diseases (CVD). Despite various drugs and treatments, the outcomes have often been unsatisfactory. The purpose of this meta-analysis aims to analyze the effects of polypill intervention on the incidence of MI and the related risk factors, blood pressure and blood lipids.</p><p><strong>Methods: </strong>We conducted a systematic search of appropriate randomized controlled trials (RCTs) in various databases, utilizing preset search terms. Then, we performed a meta-analysis of individual participant data, including studies that investigated the effectiveness of polypill (a fixed-dose combination drug) as compared to usual care in preventing MI. The primary outcomes are MI, CVD mortality, MACE and all-cause mortality. Secondary outcomes include blood pressure levels (systolic blood pressure (SBP), diastolic blood pressure (DBP)) and serum lipid levels (total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL).</p><p><strong>Results: </strong>A total of 14 trials (N = 59,346) were included, with a mean age of 63.2 ± 10.0 years. The results showed that compared to the usual care group, polypill group was associated with a significant reduction of the incidence of MI (OR = 0.76; 95% CI: 0.59 to 0.99; p = 0.04) and MACE (OR = 0.79; 95%CI: 0.65 to 0.97; p = 0.03). The risk reduction for CVD mortality (OR = 0.85; 95%CI :0.65 to 1.11; p = 0.20) and all-cause mortality (OR = 0.99; 95%CI: 0.95 to 1.03; p = 0.59) did not reach statistical significance contrast with the usual care group. Participants who were in polypill group was observed that the change of SBP level (SMD = -0.13; 95%CI: -0.25 to 0.00; p = 0.04), DBP level (SMD = -0.13; 95%CI: -0.19 to -0.06; p = 0.00) and LDL level (SMD = -0.21; 95%CI: -0.36 to -0.06; p = 0.01) reached statistical significance. However, the change of HDL level (SMD = -0.01; 95%CI: -0.06 to 0.04; p = 0.62) and TC level (SMD = -0.15; 95%CI: -0.32 to 0.01; p = 0.06) did not show remarkable difference.</p><p><strong>Conclusion: </strong>These findings suggested that polypill not only is highly effective for preventing MI and reducing the incidence of MACE, but also can lower blood pressure levels and blood lipid levels.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":" ","pages":"1-19"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546788","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Myocardial infarction (MI) is one of the leading causes of death from cardiovascular diseases (CVD). Despite various drugs and treatments, the outcomes have often been unsatisfactory. The purpose of this meta-analysis aims to analyze the effects of polypill intervention on the incidence of MI and the related risk factors, blood pressure and blood lipids.

Methods: We conducted a systematic search of appropriate randomized controlled trials (RCTs) in various databases, utilizing preset search terms. Then, we performed a meta-analysis of individual participant data, including studies that investigated the effectiveness of polypill (a fixed-dose combination drug) as compared to usual care in preventing MI. The primary outcomes are MI, CVD mortality, MACE and all-cause mortality. Secondary outcomes include blood pressure levels (systolic blood pressure (SBP), diastolic blood pressure (DBP)) and serum lipid levels (total cholesterol (TC), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL).

Results: A total of 14 trials (N = 59,346) were included, with a mean age of 63.2 ± 10.0 years. The results showed that compared to the usual care group, polypill group was associated with a significant reduction of the incidence of MI (OR = 0.76; 95% CI: 0.59 to 0.99; p = 0.04) and MACE (OR = 0.79; 95%CI: 0.65 to 0.97; p = 0.03). The risk reduction for CVD mortality (OR = 0.85; 95%CI :0.65 to 1.11; p = 0.20) and all-cause mortality (OR = 0.99; 95%CI: 0.95 to 1.03; p = 0.59) did not reach statistical significance contrast with the usual care group. Participants who were in polypill group was observed that the change of SBP level (SMD = -0.13; 95%CI: -0.25 to 0.00; p = 0.04), DBP level (SMD = -0.13; 95%CI: -0.19 to -0.06; p = 0.00) and LDL level (SMD = -0.21; 95%CI: -0.36 to -0.06; p = 0.01) reached statistical significance. However, the change of HDL level (SMD = -0.01; 95%CI: -0.06 to 0.04; p = 0.62) and TC level (SMD = -0.15; 95%CI: -0.32 to 0.01; p = 0.06) did not show remarkable difference.

Conclusion: These findings suggested that polypill not only is highly effective for preventing MI and reducing the incidence of MACE, but also can lower blood pressure levels and blood lipid levels.

预防心肌梗死的固定剂量组合(Polypill):随机对照试验的荟萃分析。
目的:心肌梗死(MI)是导致心血管疾病(CVD)死亡的主要原因之一。尽管有各种各样的药物和治疗方法,但结果往往令人不满意。本荟萃分析的目的是分析多片剂干预对心肌梗死发生率及相关危险因素、血压和血脂的影响。方法:采用预设的检索词,系统检索不同数据库中合适的随机对照试验(rct)。然后,我们对个体参与者数据进行了荟萃分析,包括调查了与常规护理相比,多药片(一种固定剂量的联合药物)在预防心肌梗死方面的有效性的研究。主要结果是心肌梗死、心血管疾病死亡率、MACE和全因死亡率。次要结局包括血压水平(收缩压(SBP)、舒张压(DBP))和血脂水平(总胆固醇(TC)、低密度脂蛋白胆固醇(LDL)和高密度脂蛋白胆固醇(HDL))。结果:共纳入14例试验(N = 59,346),平均年龄为63.2±10.0岁。结果显示,与常规护理组相比,多药片组心肌梗死发生率显著降低(OR = 0.76;95% CI: 0.59 ~ 0.99;p = 0.04)和MACE (OR = 0.79;95%CI: 0.65 ~ 0.97;P = 0.03)。心血管疾病死亡率风险降低(OR = 0.85;95%CI:0.65 ~ 1.11;p = 0.20)和全因死亡率(OR = 0.99;95%CI: 0.95 ~ 1.03;P = 0.59)与常规护理组比较,差异无统计学意义。观察复方药片组患者的收缩压水平变化(SMD = -0.13;95%CI: -0.25 ~ 0.00;p = 0.04), DBP水平(SMD = -0.13;95%CI: -0.19 ~ -0.06;p = 0.00)和LDL水平(SMD = -0.21;95%CI: -0.36 ~ -0.06;P = 0.01)差异有统计学意义。高密度脂蛋白水平变化(SMD = -0.01;95%CI: -0.06 ~ 0.04;p = 0.62)和TC水平(SMD = -0.15;95%CI: -0.32 ~ 0.01;P = 0.06),差异无统计学意义。结论:本研究提示复方多药片不仅能有效预防心肌梗死,降低MACE的发生率,还能降低血压和血脂水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiology
Cardiology 医学-心血管系统
CiteScore
3.40
自引率
5.30%
发文量
56
审稿时长
1.5 months
期刊介绍: ''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信